Biomedical Engineering Reference
In-Depth Information
151. Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with
delta-aminolaevulinic acid for nodular basal cell carcinoma using a
prior debulking technique. Br J Dermatol 2000; 142: 338-9.
152. Rhodes LE, Tsoukas MM, Anderson RR, et al. Iontophoretic delivery of
ALA provides a quantitative model for ALA pharmacokinetics and PpIX
phototoxicity in human skin. J Invest Dermatol 1997; 108: 87-91.
153. Choudry K, Brooke RC, Farrar W, et al. The effect of an iron chelating agent
on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic
acid photodynamic therapy. Br J Dermatol 2003; 149: 124-30.
154. Christensen E, Skogvoll E, Viset T, Warloe T, Sundstrm S. Photodynamic
therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in
basal cell carcinoma: a 6-year clinical and histological follow-up. J Eur
Acad Dermatol Venereol 2009; 23: 58-66.
155. Peng Q, Soler AM, Warloe T, et al. Selective distribution of porphyrins
in skin thick basal cell carcinoma after topical application of methyl
5-aminolevulinate. J Photochem Photobiol B 2001; 62: 140-5.
156. Kuijpers DI, Thissen MR, Thissen CA, et al. Similar effectiveness of
methyl aminolevulinate and 5-aminolevulinate in topical photody-
namic therapy for nodular basal cell carcinoma. J Drugs Dermatol 2006;
5: 642-5.
157. Tope WD, Menter A, El-Azhary RA, et al. Comparison of topical methyl
aminolevulinate photodynamic therapy versus placebo photodynamic
therapy in nodular BCC. J Eur Acad Dermatol Venereol 2004; 18: 413-14.
158. Foley P, Freeman M, Siller G, et al. MAL-PDT or placebo cream in nodu-
lar basal cell carcinoma: results of an Australian double-blind random-
ized multicenter study. Poster presented at the International Skin Cancer
Conference 2004, Zurich, July 22-24, 2004.
159. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using
topical methyl aminolevulinate vs surgery for nodular basal cell carci-
noma: results of a multicenter randomized prospective trial. Arch Der-
matol 2004; 140: 17-23.
160. Rhodes LE, de Rie M, Leifsdottir R, et al. Five-year follow-up of a ran-
domized, prospective trial of topical methyl aminolevulinate photody-
namic therapy vs surgery for nodular basal cell carcinoma. Arch
Dermatol 2007; 143: 1131-6.
161. Foley P, Freeman M, Menter A, Siller G, El-Azhary RA. Photodynamic
therapy with methyl aminolevulinate for primary nodular basal cell car-
cinoma: results for two randomized studies. Int J Dermatol 2009; 48:
1236-45.
162. Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recur-
rence and cosmesis in completely responding superfi cial and nodular
basal cell carcinomas treated with methyl 5-aminolaevulinate-based
photodynamic therapy alone and with prior curettage. Br J Dermatol
2001; 145: 467-71.
163. Szeimies RF. Methyl aminolevulinate-photodynamic therapy for basal
cell carcinoma. Dermatol Clin 2007; 25: 89-94.
164. Tierney E, Petersen J, Hanke CW. Photodynamic diagnosis of tumor
margins using methyl aminolevulinate before Mohs micrographic sur-
gery. J Am Acad Dermatol 2011; 64: 911-18.
165. Lee CY, Kim KH, Kim YH. The effi cacy of photodynamic diagnosis in
defi ning the lateral border between a tumor and a tumor-free area dur-
ing mohs micrographic surgery. Dermatol Surg 2010; 36: 1704-10.
166. Ruiz-Rodriguez R, Sanz-Sánchez T, Córdoba S. Photodynamic photore-
juvenation. Dermatol Surg 2002; 28: 742-4.
167. Dover JS, Bhatia AC, Stewart B, Arndt KA. Topical 5-aminolevulinic acid
combined with intense pulsed light in the treatment of photoaging. Arch
Dermatol 2005; 141: 1247-52.
168. Zane C, Capezzera R, Sala R, Venturini M, Calzavara-Pinton P. Clinical
and echographic analysis of photodynamic therapy using methylami-
nolevulinate as sensitizer in the treatment of photodamaged facial skin.
Lasers Surg Med 2007; 39: 203-9.
169. Gold MH, Bradshaw VL, Boring MM, et al. Split-face comparison of
photodynamic therapy with 5-aminolevulinic acid and intense pulsed
light versus intense pulsed light alone for photodamage. Dermatol Surg
2006; 32: 795-803.
170. Uebelhoer NS, Dover J. Photodynamic therapy for cosmetic applica-
tions. Dermatol Ther 2005; 18: 242-52.
171. Jeffes EWB. Levulan: the fi rst approved topical photosensitizer for the
treatment of actinic keratosis. J Dermatol Treat 2002; 13: S19-23.
172. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with
topical methyl aminolevulinate for actinic keratosis: Results of a pro-
spective randomized multicenter trial. J Am Acad Dermatol 2003; 48:
227-32.
173. Zane C, Capezzera R, Sala R, et al. Clinical and echographic analysis
of photodynamic therapy using methylaminolevulinate as sensitizer in the
treatment of photodamaged facial skin. Lasers Surg Med 2007; 39: 203-9.
174. Issa MCL, Pineiro-Maceira J, Vieira MTC, et al. Photorejuvenation with
topical methyl aminolevulinate and red light: a randomized, prospective,
clinical, histopathologic, and morphometric study. Dermatol Surg 2010;
36: 39-48.
175. Lowe NJ, Lowe P. Pilot study to determine the effi cacy of ALA-PDT pho-
torejuvenation for the treatment of facial ageing. J Cosmet Laser Ther
2005; 7: 159-62.
176. Park MY, Sohn S, Lee E, Kim YC. Photorejuvenation induced by
5-aminolevulinic acid photodynamic therapy in patients with actinic
keratosis: a histologic analysis. J Am Acad Dermatol 2010; 62: 85-95.
177. Goldberg DJ. New collagen formation after dermal remodeling with
intense pulsed light sources. J Cutan Laser Ther 2000; 2: 59-61.
178. Avram DK, Goldman MP. Effectiveness and safety of ALA-IPL in treating
actinic keratoses and photodamage. J Drugs Dermatol 2004; 3: S36-9.
179. Alster TS, Tanzi EL, Welch EC. Photorejuvenation of facial skin with
topical 20% 5-aminolevulinic acid and intense pulsed light treatment: a
split-face comparison study. J Drugs Dermatol 2005; 4: 35-8.
180. Marmur ES, Phelps R, Goldberg DJ. Ultrastructural changes seen after
ALA-IPL photorejuvenation: a pilot study. J Cosmet Laser Ther 2005;
7: 21-4.
181. Serrano G, Lorente M, Reyes M, et al. Photodynamic therapy with
low-strength ALA, repeated applications and short contact periods
(40-60 minutes) in acne, photoaging, and vitiligo. J Drugs Dermatol
2009; 8: 562-8.
182. Xi Z, Shuxian Y, Zhong L, et al. Topical 5-aminolevulinic acid with
intense pulsed light versus intense pulsed light for photodamage in chi-
nese patients. Dermatol Surg 2011; 37: 31-40.
183. Key DJ. Aminolevulinic acid-pulsed dye laser photodynamic therapy for
the treatment of photoaging. Cosmet Dermatol 2005; 18: 31-6.
184. Clementoni MT, B-Roscher M, Munavalli GS. Photodynamic photoreju-
venation of the face with a combination of microneedling, red light, and
broadband pulsed light. Lasers Surg Med 2010; 42: 150-9.
185. Ruiz-Rodriguez R, López L, Candelas D, Zelickson B. Enhanced effi cacy
of photodynamic therapy after fractional resurfacing: fractional photo-
dynamic rejuvenation. J Drugs Dermatol 2007; 6: 818-20.
186. Hædersdal M, Sakamoto FH, Farinelli WA, et al. Fractional CO
2
laser-
assisted drug delivery. Lasers Surg Med 2010; 42: 113-22.
187. Szeimies RM, Stockfl eth E, Popp G, et al. Long-term follow-up of photo-
dynamic therapy with self-adhesive 5-aminolaevulinic acid patch: 12
months data. Br J Dermatol 2010; 162: 410-14.
188. Warren CB, Karai LJ, Vidimos A, Maytin EV. Pain associated with ami-
nolevulinic acid-photodynamic therapy of skin disease. J Am Acad Der-
matol 2009; 61: 1033-43.
189. Tyrrell J, Campbell SM, Curnow A. The effect of air cooling pain relief
on protoporphyrin IX photobleaching and clinical effi cacy during
dermatological photodynamic therapy. J Photochem Photobiol B 2011;
103: 1-7.
190. Tyrrell J, Campbell SM, Curnow A. The relationship between proto-
porphyrin IX photobleaching during real-time dermatological methyl-
aminoluvinate photodynamic therapy (MAL-PDT) and subsequent
clinical outcome. Lasers Surg Med 2010; 42: 613-19.
191. Ascencio M, Collinet P, Farine MO, Mordon S. Protoporphyrin IX fl uo-
rescence photobleaching is a useful tool to predict the response of rat
ovarian cancer following hexaminolevulinate photodynamic therapy.
Lasers Surg Med 2008; 40: 332-41.
192. Borreli C, Herzinger T, Merk K, et al. Effect of subcutaneous infi ltration
anesthesia on pain in photodynamic therapy: a controlled open pilot
trial. Dermatol Surg 2007; 33: 314-18.
193. Attili SK, Lesar A, McNeill A, et al. An open pilot study of ambulatory
photodynamic therapy using a werable low-irradiance organic light-
emitting diode light source in the treatment of nonmelanoma skin can-
cer. Br J Dermatol 2009; 161: 170-3.
194. Wiegell SR, Hædersdal M, Philipsen PA, et al. Continuous activation of
PpIX by daylight is as effective as and less painful than conventional
photodynamic therapy for actinic keratosis: a randomized, controlled,
single-blinded study. Br J Dermatol 2008; 158: 740-6.
